TAKEDA PHARMACEUTIC-SP ADR (TAK) Stock Price, Forecast & Analysis
USA - NYSE:TAK - US8740602052 - ADR
TAK Key Statistics, Chart & Performance
The current stock price of TAK is 14.29 USD. In the past month the price increased by 1.78%. In the past year, price increased by 4.92%.
TAK Latest News, Press Relases and Analysis
TAK Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 46.62 | 970.39B | ||
| JNJ | JOHNSON & JOHNSON | 18.88 | 471.87B | ||
| MRK | MERCK & CO. INC. | 10.55 | 232.09B | ||
| PFE | PFIZER INC | 7.83 | 142.48B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.11 | 94.95B | ||
| ZTS | ZOETIS INC | 19.06 | 53.55B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.53 | 22.84B | ||
| VTRS | VIATRIS INC | 4.6 | 12.50B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.97 | 10.48B | ||
| CORT | CORCEPT THERAPEUTICS INC | 85.84 | 7.96B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 6.97B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 4.07B |
Related stock screener links
About TAK
Company Profile
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 47,455 full-time employees. The firm focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The firm focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The firm operates in Japan, the United States, Europe, and China.
Company Info
TAKEDA PHARMACEUTIC-SP ADR
4F, 2-1-1, Nihombashihon-cho
Chuo-Ku TOKYO-TO 103-8668 JP
CEO: Christophe Weber
Employees: 47455
Phone: 81332782111
TAKEDA PHARMACEUTIC-SP ADR / TAK FAQ
What does TAKEDA PHARMACEUTIC-SP ADR do?
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 47,455 full-time employees. The firm focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The firm focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The firm operates in Japan, the United States, Europe, and China.
What is the stock price of TAKEDA PHARMACEUTIC-SP ADR today?
The current stock price of TAK is 14.29 USD. The price increased by 0.35% in the last trading session.
Does TAK stock pay dividends?
TAKEDA PHARMACEUTIC-SP ADR (TAK) has a dividend yield of 4.57%. The yearly dividend amount is currently 0.62.
What is the ChartMill technical and fundamental rating of TAK stock?
TAK has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What is the Price/Earnings (PE) ratio of TAKEDA PHARMACEUTIC-SP ADR (TAK)?
The PE ratio for TAKEDA PHARMACEUTIC-SP ADR (TAK) is 204.14. This is based on the reported non-GAAP earnings per share of 0.07 and the current share price of 14.29 USD.
Would investing in TAKEDA PHARMACEUTIC-SP ADR be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on TAK.
Can you provide the short interest for TAK stock?
The outstanding short interest for TAKEDA PHARMACEUTIC-SP ADR (TAK) is 0.3% of its float.
TAK Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to TAK. When comparing the yearly performance of all stocks, TAK turns out to be only a medium performer in the overall market: it outperformed 42.89% of all stocks.
TAK Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to TAK. TAK scores excellent on profitability, but there are concerns on its financial health.
TAK Financial Highlights
Over the last trailing twelve months TAK reported a non-GAAP Earnings per Share(EPS) of 0.07. The EPS decreased by -88.38% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 0.75% | ||
| ROA | 0.23% | ||
| ROE | 0.46% | ||
| Debt/Equity | 0.61 |
TAK Forecast & Estimates
19 analysts have analysed TAK and the average price target is 16.68 USD. This implies a price increase of 16.71% is expected in the next year compared to the current price of 14.29.
For the next year, analysts expect an EPS growth of 112.39% and a revenue growth -1.23% for TAK